文献速递儿科与产科急症呼吸衰竭与机械通气

单克隆抗体预防婴幼儿呼吸道合胞病毒感染:系统评价与网状Meta分析

Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
PubMed 文献 · JAMA Netw Open · 2023-02-01
一句话结论与安慰剂相比,尼塞韦单抗、帕利珠单抗和莫维珠单抗可显著减少RSV相关感染和住院,且未显著增加药物相关不良事件。

该系统评价与网状Meta分析检索PubMed、Embase、CENTRAL和ClinicalTrials.gov(建库至2022年3月),纳入15项随机临床试验(18395例参与者),其中14项(18042例)进入合成分析。与安慰剂相比,尼塞韦单抗、帕利珠单抗和莫维珠单抗每1000例参与者分别减少RSV相关感染123、108、136例,减少RSV相关住院54、39、48例(中至高确定性证据)。莫维珠单抗和帕利珠单抗还显著减少ICU入住(每1000例分别减少8例和5例)和补充氧使用(分别减少59例和55例),尼塞韦单抗减少补充氧使用59例(中等确定性证据)。全因死亡和药物相关不良事件无显著差异;苏普塔韦单抗未显示显著获益。作者认为这些单克隆抗体在预防RSV感染方面有实质性获益,但需更多研究确认安全性及成本效益。

要点

  • 与安慰剂相比,尼塞韦单抗、帕利珠单抗和莫维珠单抗每1000例参与者分别减少RSV相关感染123例(95%CI -138至-100)、108例(95%CI -127至-82)、136例(95%CI -146至-125),证据确定性中至高。
  • 与安慰剂相比,尼塞韦单抗、帕利珠单抗和莫维珠单抗每1000例参与者分别减少RSV相关住院54例(95%CI -64至-38)、39例(95%CI -48至-28)、48例(95%CI -58至-33),证据确定性中至高。
  • 莫维珠单抗和帕利珠单抗每1000例参与者分别减少ICU入住8例(95%CI -9至-4)和5例(95%CI -7至0),减少补充氧使用59例(95%CI -63至-54)和55例(95%CI -61至-41),证据确定性中等。
  • 尼塞韦单抗每1000例参与者减少补充氧使用59例(95%CI -65至-40),证据确定性中等。
  • 全因死亡和药物相关不良事件与安慰剂相比无显著差异;苏普塔韦单抗对各项结局均未显示显著获益。

适用人群与场景

  • 纳入RSV感染高危婴儿的随机临床试验;研究进入时中位年龄3.99个月(IQR 3.25-6.58个月),男性中位比例52.37%(IQR 50.49%-53.85%)。

研究设计与关键结果

  • 研究类型:系统评价与网状Meta分析;共纳入15项随机临床试验(18395例参与者),其中14项(18042例)进入合成分析;检索PubMed、Embase、CENTRAL和ClinicalTrials.gov,建库至2022年3月。
  • 与安慰剂相比,每1000例参与者RSV相关感染减少:尼塞韦单抗-123(95%CI -138至-100)、帕利珠单抗-108(95%CI -127至-82)、莫维珠单抗-136(95%CI -146至-125),证据确定性中至高。
  • 与安慰剂相比,每1000例参与者RSV相关住院减少:尼塞韦单抗-54(95%CI -64至-38)、帕利珠单抗-39(95%CI -48至-28)、莫维珠单抗-48(95%CI -58至-33),证据确定性中至高。
  • 与安慰剂相比,每1000例参与者ICU入住减少:莫维珠单抗-8(95%CI -9至-4)、帕利珠单抗-5(95%CI -7至0),证据确定性中等。
  • 与安慰剂相比,每1000例参与者补充氧使用减少:莫维珠单抗-59(95%CI -63至-54)、帕利珠单抗-55(95%CI -61至-41)、尼塞韦单抗-59(95%CI -65至-40),证据确定性中等。
  • 全因死亡和药物相关不良事件与安慰剂相比无显著差异;苏普塔韦单抗对各项关注结局均未显示显著获益。

证据类型、等级与局限

  • 证据类型:系统评价与网状Meta分析,采用GRADE方法评定证据确定性;主要结局证据确定性为中至高,ICU入住和补充氧使用结局为中等确定性。
  • 局限:作者指出需要更多研究来确认当前结论,尤其是安全性和成本效益方面。

对床旁实践的改变

  • 作者认为,莫维珠单抗、尼塞韦单抗和帕利珠单抗在预防RSV感染方面有实质性获益,与安慰剂相比未显著增加不良事件;但需更多研究确认当前结论,尤其是安全性和成本效益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infection in children younger than 5 years; effective prevention strategies are urgently needed.

OBJECTIVE: To compare the efficacy and safety of monoclonal antibodies for the prevention of RSV infection in infants and children.

DATA SOURCES: In this systematic review and network meta-analysis, PubMed, Embase, CENTRAL, and ClinicalTrials.gov were searched from database inception to March 2022.

STUDY SELECTION: Randomized clinical trials that enrolled infants at high risk of RSV infection to receive a monoclonal antibody or placebo were included. Keywords and extensive vocabulary related to monoclonal antibodies, RSV, and randomized clinical trials were searched.

DATA EXTRACTION AND SYNTHESIS: The Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline was used. Teams of 2 reviewers independently performed literature screening, data extraction, and risk of bias assessment. The Grading of Recommendations, Assessments, Developments, and Evaluation approach was used to rate the certainty of evidence. A random-effects model network meta-analysis was conducted using a consistency model under the frequentist framework.

MAIN OUTCOMES AND MEASURES: The main outcomes were all-cause mortality, RSV-related hospitalization, RSV-related infection, drug-related adverse events, intensive care unit admission, supplemental oxygen use, and mechanical ventilation use.

RESULTS: Fifteen randomized clinical trials involving 18 395 participants were eligible; 14 were synthesized, with 18 042 total participants (median age at study entry, 3.99 months [IQR, 3.25-6.58 months]; median proportion of males, 52.37% [IQR, 50.49%-53.85%]). Compared with placebo, with moderate- to high-certainty evidence, nirsevimab, palivizumab, and motavizumab were associated with significantly reduced RSV-related infections per 1000 participants (nirsevimab: -123 [95% CI, -138 to -100]; palivizumab: -108 [95% CI, -127 to -82]; motavizumab: -136 [95% CI, -146 to -125]) and RSV-related hospitalizations per 1000 participants (nirsevimab: -54 [95% CI, -64 to -38; palivizumab: -39 [95% CI, -48 to -28]; motavizumab: -48 [95% CI, -58 to -33]). With moderate-certainty evidence, both motavizumab and palivizumab were associated with significant reductions in intensive care unit admissions per 1000 participants (-8 [95% CI, -9 to -4] and -5 [95% CI, -7 to 0], respectively) and supplemental oxygen use per 1000 participants (-59 [95% CI, -63 to -54] and -55 [95% CI, -61 to -41], respectively), and nirsevimab was associated with significantly reduced supplemental oxygen use per 1000 participants (-59 [95% CI, -65 to -40]). No significant differences were found in all-cause mortality and drug-related adverse events. Suptavumab did not show any significant benefits for the outcomes of interest.

CONCLUSIONS AND RELEVANCE: In this study, motavizumab, nirsevimab, and palivizumab were associated with substantial benefits in the prevention of RSV infection, without a significant increase in adverse events compared with placebo. However, more research is needed to confirm the present conclusions, especially for safety and cost-effectiveness.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Sun M, Lai H, Na F, et al. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis. JAMA Netw Open. 2023. PMID: 36800182. doi:10.1001/jamanetworkopen.2023.0023

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。